scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Journal ArticleDOI

A comparison of conventional and advanced electroanalytical methods to detect SARS-CoV-2 virus: A concise review

P.S. Ganesh, +1 more
- 01 Jul 2022 - 
TL;DR: In this article , a review article compares and addresses recent improvements in conventional and advanced electroanalytical approaches for detecting COVID-19 virus, including polymerase chain reaction (PCR), loop mediated isothermal amplification (LAMP), serology test, and computed tomography (CT) scan with artificial intelligence.
Journal ArticleDOI

Engineered soluble ACE2 receptor: Responding to change with change

TL;DR: In this paper , the authors proposed recombinant soluble ACE2 as an alternative therapy for SARS-CoV-2, which showed great potential for broadly neutralizing coronaviruses but its progress in clinical development remains stalled.
Journal ArticleDOI

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection

TL;DR: This study could demonstrate the high therapeutic effect of C/I with an antibody-dependent enhancement-like response and decreased IFN-I production, which was likely due to the immediate induction of an antibodies-dependent immune response against SARS-CoV-2.
Posted ContentDOI

Regulatory approved monoclonal antibodies contain framework mutations predicted from human antibody repertoires

TL;DR: In this paper, position-specific scoring matrices (PSSMs) for antibody framework mutations developed using natural human antibody repertoire sequences are presented, and mutations in existing therapeutic mAbs can be accurately predicted solely from NHR data.
Posted ContentDOI

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains

TL;DR: In this paper , a human VH domain, F6, was generated by sequentially panning large phage displayed VH libraries against receptor binding domains (RBDs) containing VOC mutations.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)